Disclosure of Erlotinib as a Multikinase Inhibitor in Pancreatic Ductal Adenocarcinoma

A placebo-controlled phase 3 trial demonstrated that the epidermal growth factor receptor (EGFR) inhibitor erlotinib in combination with gemcitabine was especially efficient in a pancreatic ductal adenocarcinoma (PDAC) subgroup of patients developing skin toxicity. However, EGFR expression was not p...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Conradt, Laura, Godl, Klaus, Schaab, Christoph, Tebbe, Andreas, Eser, Stefan, Diersch, Sandra, Michalski, Christoph W, Kleeff, Jörg, Schnieke, Angelika, Schmid, Roland M, Saur, Dieter, Schneider, Günter
Médium: Artigo
Jazyk:Inglês
Vydáno: Neoplasia Press Inc. 2011
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3223607/
https://ncbi.nlm.nih.gov/pubmed/22131878
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky